

Massimo Aglietta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3475557/massimo-aglietta-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

344
papers

14,555
citations

58
h-index

111
g-index

356
ext. papers

16,634
ext. citations

6
avg, IF

5.84
L-index

#	Paper	IF	Citations
344	HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. <i>Transplantation</i> , 2022 , 3, 51-67	1	
343	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.. <i>Frontiers in Oncology</i> , 2022 , 12, 771418	5.3	1
342	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.. <i>ESMO Open</i> , 2022 , 7, 100431	6	
341	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , 2021 , 16, 789-799	5	1
340	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101015	2.2	29
339	EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma. <i>Cells</i> , 2021 , 10,	7.9	1
338	Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. <i>Cells</i> , 2021 , 10,	7.9	2
337	Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2021 , 9,	5.3	2
336	Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Journal of Clinical Medicine</i> , 2021 ,	5.1	2
335	A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. <i>Cancers</i> , 2021 , 13,	6.6	4
334	Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. <i>European Journal of Cancer</i> , 2021 , 149, 153-164	7.5	15
333	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021 , 13,	6.6	3
332	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	
331	Tremellimumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021 , 13,	6.6	7
330	High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. <i>ESMO Open</i> , 2021 , 6, 100133	6	0
329	Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. <i>Gynecologic Oncology</i> , 2021 , 162, 80-87	4.9	1
328	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 58-58	2.2	6

327	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	4
326	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta Oncologica</i> , 2021 , 60, 1317-1324	3.2	2
325	Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients. <i>BMC Cancer</i> , 2021 , 21, 865	4.8	1
324	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2021 , 1-10	2.3	0
323	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021 , 155, 56-63	7.5	3
322	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. <i>Cancers</i> , 2020 , 12,	6.6	4
321	Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. <i>Journal of Ovarian Research</i> , 2020 , 13, 53	5.5	3
320	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. <i>Cancers</i> , 2020 , 12,	6.6	6
319	Melanoma Brain Metastases in the Era of Target Therapies: An Overview. <i>Cancers</i> , 2020 , 12,	6.6	14
318	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919899850	5.4	1
317	Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. <i>Future Oncology</i> , 2020 , 16, 15-19	3.6	1
316	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102877	7	9
315	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Lung Cancer</i> , 2020 , 139, 47-54	5.9	18
314	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , 2020 , 30, 261-267	3.3	11
313	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020 , 40, 704-711	7.9	25
312	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABITUDE study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968725	5.4	3
311	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <i>Clinical Cancer Research</i> , 2020 , 26, 6321-6334	12.9	5
310	Evolution of the Experimental Models of Cholangiocarcinoma. <i>Cancers</i> , 2020 , 12,	6.6	44

309	Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report. <i>Acta Haematologica</i> , 2020 , 143, 481-485	2.7	
308	Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer. <i>Scientific Reports</i> , 2020 , 10, 6478	4.9	3
307	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 2121-2137	4	7
306	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e394-e401	3.8	7
305	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	24
304	Preventing Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 2180-2181	59.2	1
303	Veliparib: a new therapeutic option in ovarian cancer?. <i>Future Oncology</i> , 2019 , 15, 1975-1987	3.6	5
302	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. <i>Cancers</i> , 2019 , 11,	6.6	3
301	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. <i>Cancers</i> , 2019 , 11,	6.6	14
300	Assessment of a High Sensitivity Method for Identification of R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. <i>Cancers</i> , 2019 , 11,	6.6	3
299	Met inhibition revokes IFN γ Induction of PD-1 ligands in MET-amplified tumours. <i>British Journal of Cancer</i> , 2019 , 120, 527-536	8.7	26
298	TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019 , 12, 17	5.5	13
297	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. <i>BMC Cancer</i> , 2019 , 19, 794	4.8	13
296	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 332-347.e2	3.3	6
295	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. <i>Cancers</i> , 2019 , 11,	6.6	7
294	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 219-219	2.2	3
293	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019 , 24, 385-393	5.7	15
292	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019 , 11,	6.6	30

291	Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019 , 29, 527-532	3.3	5
290	"Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 133, 17-24	7	3
289	Emerging molecular target antagonists for the treatment of biliary tract cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018 , 23, 63-75	3.7	11
288	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018 , 12, 33-37	4.5	2
287	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody. <i>Clinical Cancer Research</i> , 2018 , 24, 3377-3385	12.9	18
286	CD44v6 as innovative sarcoma target for CAR-redirectioned CIK cells. <i>Oncolmmunology</i> , 2018 , 7, e1423167	7.2	21
285	Fluoropyrimidine-induced cardiotoxicity. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 124, 1-10	7	30
284	Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. <i>Future Oncology</i> , 2018 , 14, 443-448	3.6	4
283	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 521-536	21.7	315
282	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 191-198	4.9	1
281	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two-centers experience. <i>Journal of Ovarian Research</i> , 2018 , 11, 42	5.5	16
280	Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. <i>BMC Genomics</i> , 2018 , 19, 440	4.5	10
279	Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. <i>Immunotherapy</i> , 2018 , 10, 753-767	3.8	7
278	Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. <i>Cancer Medicine</i> , 2018 , 7, 4339-4344	4.8	15
277	Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. <i>Oncolmmunology</i> , 2018 , 7, e1465161	7.2	14
276	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. <i>PLoS ONE</i> , 2018 , 13, e0191593	3.7	6
275	Improvement of metastatic colorectal cancer patient survival: Single institution experience. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15633-e15633	2.2	
274	BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report. <i>Melanoma Research</i> , 2018 , 28, 143-146	3.3	2

273	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 773-779	2.2	938
272	PARP Inhibitors in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018 , 13, 392-410	2.6	60
271	Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. <i>Annals of Oncology</i> , 2018 , 29, 2288-2295	10.3	35
270	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1581-S1601	16.0	38
269	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1451-1463	4	2
268	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , 2018 , 19, 1360-1371	21.7	38
267	Role of interferon in melanoma: old hopes and new perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 475-483	5.4	13
266	Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2017 , 78, 122-132	7.5	17
265	Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26650	3	1
264	Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 459-466	4.7	38
263	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017 , 8, 90532-90544	3.3	60
262	Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. <i>Molecular Medicine</i> , 2017 , 23, 235-246	6.2	9
261	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017 , 83, 106-115	7.5	21
260	Treating breast cancer with cell-based approaches: an overview. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1255-1264	5.4	4
259	Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 118, 1-6	7	10
258	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017 , 82, 16-24	7.5	28
257	Alpha-fetoprotein elevation in NUT midline carcinoma: a case report. <i>BMC Cancer</i> , 2017 , 17, 266	4.8	11
256	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. <i>Molecular Cancer</i> , 2017 , 16, 86	42.1	37

255	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 2277-2288	12.9	25
254	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 731-739	5.4	14
253	Androgen receptor status predicts development of brain metastases in ovarian cancers. <i>Oncotarget</i> , 2017 , 8, 41143-41153	3.3	8
252	Treatment of metastatic melanoma: a multidisciplinary approach. <i>Italian Journal of Dermatology and Venereology</i> , 2017 , 152, 241-261	1.2	3
251	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. <i>BMC Cancer</i> , 2016 , 16, 793	4.8	6
250	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. <i>Journal of Translational Medicine</i> , 2016 , 14, 119	8.5	11
249	Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016 , 2, 445-52	13.4	40
248	Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. <i>Tumor Biology</i> , 2016 , 37, 4041-52	2.9	23
247	Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. <i>Oncotarget</i> , 2016 , 7, 52354-52363	3.3	13
246	Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. <i>Oncotarget</i> , 2016 , 7, 86766-86780	3.3	8
245	Xenopatient show the need for precision medicine approach to chemotherapy in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 26181-91	3.3	13
244	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. <i>Oncotarget</i> , 2016 , 7, 37680 ³³ 37692 ³⁰		
243	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	41
242	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). <i>Cancer</i> , 2016 , 122, 574-81	6.4	96
241	Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. <i>BMC Cancer</i> , 2016 , 16, 90	4.8	26
240	Adoptive immunotherapy against ovarian cancer. <i>Journal of Ovarian Research</i> , 2016 , 9, 30	5.5	25
239	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. <i>Gynecologic Oncology</i> , 2015 , 138, 627-33	4.9	30
238	Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. <i>Journal of Translational Medicine</i> , 2015 , 13, 01	8.5	1

237	The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. <i>BMC Cancer</i> , 2015 , 15, 374	4.8	20
236	A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients. <i>Breast Journal</i> , 2015 , 21, 241-5	1.2	10
235	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1491-500	5.4	4
234	Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. <i>Immunotherapy</i> , 2015 , 7, 999-1010	3.8	21
233	Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. <i>Chronobiology International</i> , 2015 , 32, 1359-66	3.6	1
232	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology</i> , 2015 , 16, 98-107	21.7	195
231	Adoptive immunotherapy against sarcomas. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 517-28	5.4	9
230	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014 , 110, 2165-9	8.7	56
229	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014 , 8, 20-6	7.9	34
228	Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. <i>Cancer Research</i> , 2014 , 74, 119-29	10.1	57
227	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. <i>Breast</i> , 2014 , 23, 44-9	3.6	20
226	Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. <i>BMC Research Notes</i> , 2014 , 7, 529	2.3	19
225	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 30	12.8	76
224	Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1259-70	5.4	17
223	Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014 , 12, 116	8.5	130
222	Metastatic breast cancer subtypes and central nervous system metastases. <i>Breast</i> , 2014 , 23, 623-8	3.6	64
221	Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 218-26	7	10
220	Recent advances in the development of breast cancer vaccines. <i>Breast Cancer: Targets and Therapy</i> , 2014 , 6, 159-68	3.9	16

219	Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. <i>OncolImmunology</i> , 2014 , 3, e28269	7.2	2
218	Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. <i>BMC Cancer</i> , 2014 , 14, 918	4.8	6
217	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2014 , 25, 1750-1755	10.3	131
216	Anticoagulation for central venous catheters in patients with cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1362-3	59.2	18
215	Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 1033-40	5	21
214	Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. <i>Current Gene Therapy</i> , 2014 , 14, 52-62	4.3	18
213	Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014 , 14, 211-22	2.2	2
212	Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. <i>Cancer</i> , 2013 , 119, 277-84	6.4	65
211	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. <i>Cancer</i> , 2013 , 119, 3429-35	6.4	23
210	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). <i>Medical Oncology</i> , 2013 , 30, 581	3.7	9
209	Duration of trastuzumab for HER2-positive breast cancer. <i>Lancet Oncology, The</i> , 2013 , 14, 678-9	21.7	3
208	Biliary tract carcinomas: from chemotherapy to targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 136-48	7	33
207	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. <i>Clinical Cancer Research</i> , 2013 , 19, 2117-31	12.9	83
206	What can we learn from the ZOOM trial?--AuthorsPreply. <i>Lancet Oncology, The</i> , 2013 , 14, e388-90	21.7	1
205	Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. <i>Lancet Oncology, The</i> , 2013 , 14, 663-70	21.7	138
204	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP) 2013 , 1,		4
203	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. <i>Annals of Oncology</i> , 2013 , 24, 1740-1748	10.3	63
202	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. <i>Bone Marrow Transplantation</i> , 2013 , 48, 414-8	4.4	14

201	Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. <i>Clinical Cancer Research</i> , 2013 , 19, 4347-58	12.9	66
200	Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature. <i>Oncology Research</i> , 2013 , 20, 483-90	4.8	3
199	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9070-9070	2.2	6
198	Targeted agents: how can we improve the outcome in biliary tract cancer?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013 , 2, 31-3	2.1	3
197	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <i>Cancer</i> , 2012 , 118, 17-26	6.4	49
196	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 379, 1879-86	4.0	1395
195	Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1600-7	4.7	21
194	Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. <i>Annals of Surgical Oncology</i> , 2012 , 19, 3755-61	3.1	15
193	Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 673-84	5.4	107
192	A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. <i>Oncology Letters</i> , 2012 , 3, 819-824	2.6	11
191	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012 , 4, 131-7	3.9	11
190	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. <i>Annals of Oncology</i> , 2012 , 23, 508-16	10.3	229
189	¹⁵³ Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. <i>Annals of Oncology</i> , 2012 , 23, 1899-905	10.3	23
188	In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. <i>European Radiology</i> , 2012 , 22, 1131-9	8	13
187	Correlations between diffusion-weighted imaging and breast cancer biomarkers. <i>European Radiology</i> , 2012 , 22, 1519-28	8	164
186	The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. <i>Oncologist</i> , 2012 , 17, 1430-8	5.7	55
185	Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1528-38	6.1	13
184	Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. <i>Oncologist</i> , 2012 , 17, 1418-25	5.7	35

183	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012 , 23, 2072-2077	10.3	82
182	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2143-56	4	6
181	Imaging as a potential tool for subtyping breast cancer. <i>Imaging in Medicine</i> , 2012 , 4, 577-579	1	
180	Gingival metastasis of a radiotherapy-induced breast angiosarcoma: diagnosis and multidisciplinary treatment achieving a prolonged complete remission. <i>Anti-Cancer Drugs</i> , 2012 , 23, 1112-7	2.4	6
179	Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. <i>Journal of Immunotherapy</i> , 2012 , 35, 579-86	5	20
178	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10009-10009	2.2	2
177	Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15073-e15073	2.2	
176	Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. <i>Journal of Biotechnology</i> , 2011 , 156, 218-26	3.7	13
175	Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011 , 8, 161-177		
174	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011 , 117, 6721-7	2.2	97
173	Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. <i>Blood</i> , 2011 , 117, 419-28	2.2	109
172	Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. <i>British Journal of Cancer</i> , 2011 , 104, 1686-90	8.7	56
171	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. <i>Annals of Oncology</i> , 2011 , 22, 1614-1621	10.3	36
170	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 29-40	4.4	37
169	Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. <i>Advances in Therapy</i> , 2011 , 28, 684-97	4.1	14
168	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. <i>BMC Cancer</i> , 2011 , 11, 31	4.8	68
167	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor- β : An Italian Sarcoma Group study. <i>Cancer</i> , 2011 , 117, 826-31	6.4	31
166	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 549-65	4	7

165	Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities. <i>Oncologist</i> , 2011 , 16, 534-6	5.7	1
164	Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 655-66	5.4	2
163	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised RISCADP trial. <i>Annals of Oncology</i> , 2011 , 22, 1236-1242	10.3	85
162	Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e691-3	2.2	34
161	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 147-51	4.8	55
160	Preoperation Chemotherapy. <i>Updates in Surgery Series</i> , 2011 , 75-100	0.1	
159	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010 , 2, 93-109	3.9	6
158	Underuse of anthracyclines in women with HER-2+ advanced breast cancer. <i>Oncologist</i> , 2010 , 15, 665-72	5.7	8
157	Anthracycline-based adjuvant chemotherapy in breast cancer. <i>Lancet, The</i> , 2010 , 375, 1871; author reply 1871-2	4.0	
156	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. <i>BMC Cancer</i> , 2010 , 10, 28	4.8	13
155	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. <i>BMC Cancer</i> , 2010 , 10, 631	4.8	128
154	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , 2010 , 58, 906-11	10.2	48
153	Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. <i>British Journal of Surgery</i> , 2010 , 97, 1354-62	5.3	70
152	Trastuzumab beyond disease progression: case closed?. <i>Journal of Clinical Oncology</i> , 2009 , 27, e121-2; author reply e124-5	2.2	5
151	Reply to A. Sánchez-Muñoz et al. <i>Journal of Clinical Oncology</i> , 2009 , 27, e257-e258	2.2	
150	Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. <i>Endocrine-Related Cancer</i> , 2009 , 16, 1091-102	5.7	23
149	Aromatase inhibitors as adjuvant therapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2566-72	7.2	7
148	Translocation-related sarcomas. <i>Seminars in Oncology</i> , 2009 , 36, 312-23	5.5	58

147	Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. <i>Cancer</i> , 2009 , 115, 2980-7	6.4	41
146	Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene. <i>Stem Cells</i> , 2009 , 27, 2815-23	5.8	9
145	Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 831-40	5.4	44
144	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the RISCAD-alternating schedule study findings. <i>European Journal of Cancer</i> , 2009 , 45, 65-73	7.5	47
143	Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 326-35	4.7	24
142	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. <i>Molecular Cancer</i> , 2009 , 8, 118	42.1	131
141	An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 640-1	2.7	16
140	Poor prognosis osteosarcoma: new therapeutic approach. <i>Bone Marrow Transplantation</i> , 2008 , 41 Suppl 2, S131-4	4.4	25
139	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. <i>BMC Cancer</i> , 2008 , 8, 209	4.8	8
138	Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. <i>Clinical Breast Cancer</i> , 2008 , 8, 436-42	3	21
137	Refreezing of cord blood hematopoietic stem cells for allogeneic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions. <i>Experimental Hematology</i> , 2008 , 36, 235-43	3.1	14
136	Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. <i>International Immunology</i> , 2008 , 20, 841-8	4.9	88
135	Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2052-3; author reply 2053-4	2.2	10
134	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 256-67		68
133	Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. <i>Anti-Cancer Drugs</i> , 2008 , 19, 689-96	2.4	7
132	Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectors. <i>Stem Cells</i> , 2008 , 26, 1620-7	5.8	8
131	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 977-84	10.3	406
130	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. <i>European Radiology</i> , 2007 , 17, 1490-7	8	45

129	Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. <i>Acta Oncologica</i> , 2007 , 46, 664-8	3.2	42
128	Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 398-9		2
127	A comparison of allografting with autografting for newly diagnosed myeloma. <i>New England Journal of Medicine</i> , 2007 , 356, 1110-20	59.2	410
126	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 257-68	5.4	84
125	Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. <i>Annals of Oncology</i> , 2007 , 18, 1963-8	10.3	9
124	Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1145; author reply 1145-6	2.2	5
123	Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours. <i>European Journal of Cancer</i> , 2007 , 43, 885-90	7.5	7
122	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1179-88	4	
121	Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. <i>British Journal of Surgery</i> , 2006 , 93, 1001-6	5.3	62
120	Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. <i>Journal of Cellular Biochemistry</i> , 2006 , 97, 744-54	4.7	247
119	Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer. <i>Journal of Chemotherapy</i> , 2006 , 18, 90-7	2.3	5
118	Trastuzumab treatment in breast cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 2186; author reply 2186	59.2	9
117	Jaw complications in breast and prostate cancer patients treated with zoledronic acid. <i>Acta Oncologica</i> , 2006 , 45, 216-7	3.2	18
116	Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 1680-5	12.9	136
115	Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. <i>Oncologist</i> , 2006 , 11, 318-24	5.7	105
114	High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. <i>Annals of Oncology</i> , 2006 , 17, 1479-88	10.3	34
113	The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. <i>British Journal of Cancer</i> , 2006 , 95, 13-20	8.7	30
112	Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 68-74	4.7	5

111	Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. <i>Clinical Radiology</i> , 2006 , 61, 338-47	2.9	36
110	Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. <i>Blood</i> , 2006 , 107, 3795-803	2.2	41
109	Serial transplantations in nonobese diabetic/severe combined immunodeficiency mice of transduced human CD34+ cord blood cells: efficient oncoretroviral gene transfer and ex vivo expansion under serum-free conditions. <i>Stem Cells</i> , 2006 , 24, 1201-12	5.8	8
108	Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. <i>Annals of Surgical Oncology</i> , 2006 , 13, 1201-8	3.1	117
107	Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach. <i>Diseases of the Colon and Rectum</i> , 2006 , 49, 1596-601	3.1	21
106	Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. <i>Oncology</i> , 2005 , 68, 493-9	3.6	40
105	A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. <i>British Journal of Cancer</i> , 2005 , 92, 1261-7	8.7	23
104	Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1055-72	4	5
103	Allogeneic hemopoietic stem cell transplantation in solid tumors. <i>Transplantation Proceedings</i> , 2005 , 37, 2664-6	1.1	7
102	Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 77-80	3	17
101	Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. <i>European Radiology</i> , 2005 , 15, 1224-33	8	33
100	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005 , 24, 3002-10	9.2	101
99	Feasibility of cord blood stem cell manipulation with high-energy shock waves: an in vitro and in vivo study. <i>Experimental Hematology</i> , 2005 , 33, 1371-87	3.1	8
98	The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. <i>Cancer</i> , 2005 , 103, 1314-5; author reply 1315	6.4	4
97	Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3871-2; author reply 3872-3	2.2	27
96	Continuation of trastuzumab beyond disease progression. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2866-8; discussion 2868-9	2.2	18
95	Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. <i>Clinical Cancer Research</i> , 2005 , 11, 490-7	12.9	81
94	Vasculogenic potential of long term repopulating cord blood progenitors. <i>FASEB Journal</i> , 2004 , 18, 1273-5	5.9	19

93	A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. <i>Oncology</i> , 2004 , 66, 38-45	3.6	45
92	Trastuzumab-based combination therapy for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 81-96	4	39
91	Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. <i>Acta Radiologica</i> , 2004 , 45, 71-4	2	20
90	Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. <i>Breast Cancer Research and Treatment</i> , 2004 , 83, 67-76	4.4	207
89	Fast but durable megakaryocyte repopulation and platelet production in NOD/SCID mice transplanted with ex-vivo expanded human cord blood CD34+ cells. <i>Stem Cells</i> , 2004 , 22, 135-43	5.8	33
88	HER2 and central nervous system metastasis in patients with breast cancer. <i>Clinical Breast Cancer</i> , 2004 , 5, 232-4	3	7
87	A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004 , 5, 50-5		28
86	Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. <i>Blood</i> , 2004 , 103, 4440-8	2.2	78
85	Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). <i>Journal of Clinical Oncology</i> , 2004 , 22, 9021-9021	2.2	1
84	Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 95-7	2.7	25
83	Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?. <i>Oncology</i> , 2003 , 64, 186-8	3.6	14
82	Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability. <i>Breast Cancer Research and Treatment</i> , 2003 , 82, 185-90	4.4	8
81	Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. <i>Experimental Hematology</i> , 2003 , 31, 261-70	3.1	72
80	ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. <i>British Journal of Cancer</i> , 2003 , 88, 396-400	8.7	17
79	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. <i>Journal of Leukocyte Biology</i> , 2003 , 74, 593-601	6.5	15
78	Regression of metastatic osteosarcoma following non-myeloablative stem cell transplantation. A case report. <i>Haematologica</i> , 2003 , 88, ECR16	6.6	5
77	High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2150-6	2.2	124
76	Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo study. <i>Bone Marrow Transplantation</i> , 2002 , 29, 443-8	4.4	11

75	Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. <i>Blood</i> , 2002 , 100, 4391-400	2.2	76
74	MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors. <i>The Hematology Journal</i> , 2002 , 3, 105-13		8
73	Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. <i>Bone Marrow Transplantation</i> , 2001 , 27, 517-23	4.4	15
72	Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2001 , 15, 38-48	0.7	18
71	Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. <i>Haematologica</i> , 2001 , 86, 1099-100	6.6	215
70	Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. <i>Cancer</i> , 2000 , 88, 454-60	6.4	10
69	The involvement of human-nuc gene in polyploidization of K562 cell line. <i>Experimental Hematology</i> , 2000 , 28, 1432-40	3.1	11
68	Ex vivo expansion of megakaryocytes. <i>Transfusion Science</i> , 2000 , 22, 107-10		5
67	Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000 , 9, 945-56		24
66	High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. <i>Clinical Breast Cancer</i> , 2000 , 1, 197-209; discussion 210	3	6
65	Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells. <i>Blood</i> , 1999 , 93, 3736-3749	2.2	273
64	Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells. <i>Blood</i> , 1999 , 93, 3736-3749	2.2	12
63	Role of Hematopoietic Growth Factors on the ex Vivo Expansion of Primitive Cord Blood Stem Cells 1999 , 39-50		
62	Ex vivo expansion of cord blood progenitors. <i>Vox Sanguinis</i> , 1998 , 74 Suppl 2, 457-62	3.1	13
61	Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation. <i>Leukemia</i> , 1998 , 12, 718-27	10.7	110
60	The role of c-Mpl ligands in the expansion of cord blood hematopoietic progenitors. <i>Stem Cells</i> , 1998 , 16 Suppl 2, 243-8	5.8	11
59	Ex vivo expansion of hematopoietic cells and their clinical use. <i>Haematologica</i> , 1998 , 83, 824-48	6.6	13
58	Activation of JAK2 in Human Vascular Endothelial Cells by Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1997 , 89, 863-872	2.2	37

57	Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood. <i>Blood</i> , 1997 , 89, 2644-2653	2.2	398
56	Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl. <i>Leukemia</i> , 1997 , 11, 531-40	10.7	15
55	Flow cytometric detection and quantitative analysis of the GM-CSF receptor in human granulocytes and comparison with the radioligand binding assay. <i>Cytometry</i> , 1996 , 24, 374-81		10
54	The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. <i>Experimental Hematology</i> , 1996 , 24, 340-6	3.1	22
53	Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. <i>Blood</i> , 1995 , 86, 4105-4114	2.2	67
52	A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. <i>European Journal of Cancer</i> , 1995 , 31A, 46-9	7.5	5
51	Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiology. <i>European Journal of Clinical Investigation</i> , 1995 , 25, 68-70	4.6	22
50	Platelet activating factor produced in vitro by KaposiB sarcoma cells induces and sustains in vivo angiogenesis. <i>Journal of Clinical Investigation</i> , 1995 , 96, 940-52	15.9	85
49	Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-alpha or interleukin-1 alpha. <i>European Journal of Immunology</i> , 1994 , 24, 3131-9	6.1	29
48	GM-CSF and dose escalation of chemotherapy. <i>Annals of Oncology</i> , 1994 , 5, 663	10.3	
47	Human endothelial cells are targets for platelet-activating factor (PAF). Activation of alpha and beta protein kinase C isozymes in endothelial cells stimulated by PAF. <i>Journal of Biological Chemistry</i> , 1994 , 269, 2877-86	5.4	59
46	Rationale for the use of granulocyte-macrophage colony-stimulating factor in oncology. <i>Seminars in Oncology</i> , 1994 , 21, 5-9	5.5	9
45	Granulocyte-macrophage colony stimulating factor and interleukin 3: target cells and kinetics of response in vivo. <i>Stem Cells</i> , 1993 , 11 Suppl 2, 83-7	5.8	7
44	Transmission of hepatitis C via blood splash into conjunctiva. <i>Scandinavian Journal of Infectious Diseases</i> , 1993 , 25, 270-1		118
43	Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. <i>Cancer</i> , 1993 , 72, 2970-3	6.4	28
42	Haemopoietic growth factors in oncology. <i>Pharmacological Research</i> , 1992 , 26 Suppl 2, 80-1	10.2	
41	Essential thrombocythemia: impaired regulation of megakaryocyte progenitors. <i>International Journal of Cell Cloning</i> , 1991 , 9, 43-56		23
40	Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. <i>British Journal of Haematology</i> , 1991 , 79, 451-6	4.5	16

39	Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1991 , 52, 63-9		6
38	Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. <i>Cancer Genetics and Cytogenetics</i> , 1991 , 55, 235-41		4
37	In vivo effect of human granulocyte-macrophage colony-stimulating factor on megakaryocytopoiesis. <i>Blood</i> , 1991 , 77, 1191-1194	2.2	40
36	In vivo priming of human normal neutrophils by granulocyte-macrophage colony stimulating factor: effect on the production of platelet activating factor. <i>British Journal of Haematology</i> , 1990 , 75, 333-9	4.5	10
35	Human GM-CSF in vivo: identification of the target cells and of their kinetics of response. <i>International Journal of Cell Cloning</i> , 1990 , 8 Suppl 1, 283-90; discussion 290-2		5
34	Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Reduces Pancytopenia After Rescue Therapy in a Patient with Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1990 , 3, 61-6	1.9	
33	Effect of Hemopoietic Growth Factors on the Proliferation of Acute Myeloid and Lymphoid Leukemias. <i>Leukemia and Lymphoma</i> , 1990 , 2, 207-14	1.9	3
32	GM-CSF: intravenous versus subcutaneous treatment. <i>Leukemia</i> , 1990 , 4, 523	10.7	5
31	Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. <i>Nature</i> , 1989 , 337, 471-3	50.4	558
30	Interaction of transforming growth factor-beta 1 with hemopoietic growth factors in the regulation of human normal and leukemic myelopoiesis. <i>Experimental Hematology</i> , 1989 , 17, 296-9	3.1	19
29	Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. <i>Journal of Clinical Investigation</i> , 1989 , 83, 551-7	15.9	112
28	Effect of interferon-gamma on HLA class II antigen expression and sensitivity to prostaglandin E1 by normal and leukemic myeloid progenitors. <i>Leukemia Research</i> , 1988 , 12, 299-303	2.7	
27	Autologous Bone Marrow Transplantation in Acute Lymphoblastic Leukemia. Mafosfamide Italian Study Group. <i>Plant Systematics and Evolution Supplementum = Entwicklungsgeschichte Und Systematik Der Pflanzen Supplementum</i> , 1988 , 89-93		
26	Studies on the mechanism of interleukin 1 stimulation of platelet activating factor synthesis in human endothelial cells in culture. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1987 , 927, 43-54	4.9	33
25	Autologous bone marrow transplantation in acute leukemia. <i>Acta Haematologica</i> , 1987 , 78 Suppl 1, 190-3.7		2
24	7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis. <i>Cytotechnology</i> , 1987 , 1, 37-40	2.2	
23	Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. <i>Leukemia Research</i> , 1987 , 11, 285-90	2.7	5
22	Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. <i>Journal of Immunology</i> , 1987 , 139, 2439-46	5.3	144

21	Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells. <i>Molecular and Cellular Biology</i> , 1986 , 6, 1803-11	4.8	60
20	Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells. <i>Pharmacological Research Communications</i> , 1986 , 18 Suppl, 133-7		14
19	Human gamma interferon enhances release from phytohemagglutinin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. <i>Blood</i> , 1986 , 68, 1339-1347	2.2	26
18	Human gamma interferon enhances release from phytohemagglutinin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. <i>Blood</i> , 1986 , 68, 1339-47	2.2	8
17	Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. <i>Cancer Research</i> , 1986 , 46, 1783-7	10.1	12
16	Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. <i>Journal of Clinical Investigation</i> , 1986 , 77, 2027-33	15.9	196
15	In-vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis. <i>Leukemia Research</i> , 1985 , 9, 879-83	2.7	13
14	H2 receptor antagonists and human granulopoiesis. <i>Experientia</i> , 1985 , 41, 375-6		6
13	Retinoic acid enhances the growth of only one subpopulation of granulomonocyte precursors. <i>Acta Haematologica</i> , 1984 , 71, 97-9	2.7	7
12	Differences in the in vitro growth pattern of fresh and cryopreserved granulo-monopoietic precursors. <i>Cryobiology</i> , 1984 , 21, 486-90	2.7	6
11	Biosynthesis and release of platelet-activating factor from human monocytes. <i>International Archives of Allergy and Immunology</i> , 1983 , 70, 245-51	3.7	49
10	The release of platelet-activating factor from human endothelial cells in culture. <i>Journal of Immunology</i> , 1983 , 131, 2397-403	5.3	332
9	Responsiveness to prostaglandin E1 of different subtypes of normal and pathological committed granulomonopoietic precursors. <i>Acta Haematologica</i> , 1983 , 69, 376-81	2.7	2
8	Myelofibrosis and prostaglandins: effect of prostaglandin E1 on colony-forming cells (CFU-GM). <i>British Journal of Haematology</i> , 1981 , 48, 167-9	4.5	4
7	Effect of lithium on normal and chronic granulocytic leukemia colony forming cells (CFU-GM). <i>Experientia</i> , 1981 , 37, 1340-1		3
6	Detection of basophils growing in semisolid agar culture. <i>Experimental Hematology</i> , 1981 , 9, 95-100	3.1	13
5	Normal and leukaemic granulopoiesis. <i>Haematologica</i> , 1981 , 66, 1-17	6.6	2
4	Insensitivity of chronic myeloid leukemia cells to inhibition of growth by prostaglandin E1. <i>Cancer Research</i> , 1980 , 40, 2507-11	10.1	37

3	The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML). <i>Cancer Chemotherapy and Pharmacology</i> , 1978 , 1, 219-23	3.5	12
2	Short-term effects of colcemid on the rapid axonal transport of proteins in the optic pathway of chick embryos. <i>Experientia</i> , 1973 , 29, 1126-7		6
1	The development of axonal transport of proteins and glycoproteins in the optic pathway of chick embryos. <i>Brain Research</i> , 1973 , 63, 273-84	3.7	36